Description
Seeking people aged 5-60 newly diagnosed with early (Stage I or II) Hodgkin lymphoma that has not yet been treated for a study comparing the effect of adding immunotherapy to the standard chemotherapy to the standard chemotherapy alone.
Overview
After receiving 2 months of standard ABVD chemotherapy treatment, participants in this study will be randomly assigned to
What we're hoping for
We are comparing the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone for people with stage I and II classical Hodgkin lymphoma.
Additional Information
ClinicalTrials.gov Identifier: NCT05675410